Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
The current price of 01P.XETRA is €488.40 EUR — it has decreased by -1.47% in the past 24 hours. Watch Medpace stock price performance more closely on the chart.
What is Medpace stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Medpace stocks are traded under the ticker 01P.XETRA.
What is Medpace market cap?▼
Today Medpace has the market capitalization of 13.95B
When is the next Medpace earnings date?▼
Medpace is going to release the next earnings report on July 22, 2026.
What were Medpace earnings last quarter?▼
01P.XETRA earnings for the last quarter are 3.66 EUR per share, whereas the estimation was 3.35 EUR resulting in a +9.17% surprise. The estimated earnings for the next quarter are N/A EUR per share.